Search PubMed⌕ Search

Biomedical subjects

P S White

Publications and source records attributed to P S White.

At least 19 recordsLinked to original sources
PubMed2002

A randomized control trial of post-operative care following endoscopic sinus surgery: debridement versus no debridement.

Endoscopic sinus surgery (ESS) has undergone exponential growth worldwide in the last decade. It is now accepted as a safe and effective means of treating sinonasal disease. The purpose of this study was to determine whether post-operative debridement is necessary after ESS. Seventeen patients undergoing bilateral primary ESS were randomized to receive debridement of either the left or right ethmoid cavity. All patients included in the study had symmetrical disease. Saline douches and all other concomitant treatments were delivered bilaterally. Outcome measures were based on regular symptom scores and surgeons' semi-quantitative assessment of the debrided and non-debrided cavities, over a three-month period. Analysis of adhesion rates, healing and symptom scores showed no statistically significant difference between the two groups. In conclusion, this study did not demonstrate significant benefit from post-operative ESS cavity debridement, at least with regard to cavity healing. This should be considered a pilot study and therefore limited conclusions can be drawn. Further work is needed to determine the optimum post-operative care for ESS.

Adolescent↗
PubMed2001

Redox chemistry of morpholine-based Os(VI)-hydrazido complexes: trans-[Os(VI)(tpy)(Cl)2(NN(CH2)4O)](2+).

The oxidations of benzyl alcohol, PPh3, and the sulfides (SEt2 and SPh2) (Ph = phenyl and Et = ethyl) by the Os(VI)-hydrazido complex trans-[Os(VI)(tpy)(Cl)2(NN(CH2)4O)](2+) (tpy = 2,2':6',2' '-terpyridine and O(CH2)4N(-) = morpholide) have been investigated in CH3CN solution by UV-visible monitoring and product analysis by gas chromatography-mass spectrometry. For benzyl alcohol and the sulfides, the rate law for the formation of the Os(V)-hydrazido complex, trans-[Os(V)(tpy)(Cl)2(NN(CH2)4O)](+), is first order in both trans-[Os(VI)(tpy)(Cl)2(NN(CH2)4O)](2+) and reductant, with k(benzyl) (25.0 +/- 0.1 degrees C, CH3CN) = (1.80 +/- 0.07) x 10(-4) M(-1) s(-1), k(SEt2) = (1.33 +/- 0.02) x 10(-1) M(-1) s(-1), and k(SPh2) = (1.12 +/- 0.05) x 10(-1) M(-1) s(-1). Reduction of trans-[Os(VI)(tpy)(Cl)2(NN(CH2)4O)](2+) by PPh3 is rapid and accompanied by isomerization and solvolysis to give the Os(IV)-hydrazido product, cis-[Os(IV)(tpy)(NCCH3)2(NN(CH2)4O)](2+), and OPPh3. This reaction presumably occurs by net double Cl-atom transfer to PPh3 to give Cl2PPh3 that subsequently undergoes hydrolysis by trace H2O to give the final product, OPPh3. In the X-ray crystal structure of the Os(IV)-hydrazido complex, the Os-N-N angle of 130.9(5) degrees and the Os-N bond length of 1.971(7) A are consistent with an Os-N double bond.

Journal Article↗
PubMed2001

Synthesis, structure, and electronic properties of monomeric and dimeric trispyrazolylborate platinum(II) hydride complexes.

Tp'PtMe(H)2 (2) [Tp' = hydridotris(3,5-dimethylpyrazolyl)borate] has been prepared from Tp'PtMe(CO) (1) via reaction with water in a basic acetone/water mixture. Protonation of 2 at one of the pyrazole nitrogen atoms induces methane elimination, and the resulting platinum(II) monohydride solvent intermediate (3) can be trapped by added ligand. Two chiral cationic platinum(II) monohydride complexes of the type [kappa(2)-((Hpz)BHpz2)Pt(H)(L)][BAr'4] [L = MeCN (4), CH2=CH2 (5); pz = 3,5-dimethylpyrazolyl, BAr'4 = tetrakis(3,5-trifluoromethylphenyl)borate] have been isolated. If 2 is protonated in the absence of trapping ligand, a deep red hydride-bridged dinuclear complex, [kappa(2)-((Hpz)BHpz2)Pt(mu-H)]2[BAr'4]2 (6), forms. DFT calculations supplement intuitive expectations regarding 3-center-2-electron bridging orbital descriptions for the electronic structure of this complex. X-ray structure determinations for the monomeric acetonitrile adduct 4 and the dicationic dimer 6 are reported.

Boron Compounds↗
PubMed2001

Redox-induced terpyridyl substitution in the Os(VI)-hydrazido complex, trans-[Os(VI)(tpy)(Cl)(2)(NN(CH(2))(4)O)](2+).

Reaction between the Os(VI)-hydrazido complex, trans-[Os(VI)(tpy)(Cl)(2)(NN(CH(2))(4)O)](2+) (tpy = 2,2':6',2"-terpyridine and O(CH(2))(4)N(-) = morpholide), and a series of N- or O-bases gives as products the substituted Os(VI)-hydrazido complexes, trans-[Os(VI)(4'-RNtpy)(Cl)(2)(NN(CH(2))(4)O)](2+) or trans-[Os(VI)(4'-ROtpy)(Cl)(2)(NN(CH(2))(4)O)](2+) (RN(-) = anilide (PhNH(-)); S,S-diphenyl sulfilimide (Ph(2)S=N(-)); benzophenone imide (Ph(2)C=N(-)); piperidide ((CH(2))(5)N(-)); morpholide (O(CH(2))(4)N(-)); ethylamide (EtNH(-)); diethylamide (Et(2)N(-)); and tert-butylamide (t-BuNH(-)) and RO(-) = tert-butoxide (t-BuO(-)) and acetate (MeCO(2)(-)). The rate law for the formation of the morpholide-substituted complex is first order in trans-[Os(VI)(tpy)(Cl)(2)(NN(CH(2))(4)O)](2+) and second order in morpholine with k(morp)(25 degrees C, CH(3)CN) = (2.15 +/- 0.04) x 10(6) M(-)(2) s(-)(1). Possible mechanisms are proposed for substitution at the 4'-position of the tpy ligand by the added nucleophiles. The key features of the suggested mechanisms are the extraordinary electron withdrawing effect of Os(VI) on tpy and the ability of the metal to undergo intramolecular Os(VI) to Os(IV) electron transfer. These substituted Os(VI)-hydrazido complexes can be electrochemically reduced to the corresponding Os(V), Os(IV), and Os(III) forms. The Os-N bond length of 1.778(4) A and Os-N-N angle of 172.5(4) degrees in trans-[Os(VI)(4'-O(CH(2))(4)Ntpy)(Cl)(2)(NN(CH(2))(4)O)](2+) are consistent with sp-hybridization of the alpha-nitrogen of the hydrazido ligand and an Os-N triple bond. The extensive ring substitution chemistry implied for the Os(VI)-hydrazido complexes is discussed.

Journal Article↗
PubMed2001

Reversible osmium(VI) nitrido to osmium(II) ammine interconversion in complexes containing polypyrazolyl ligands.

This paper describes the 4e-/3H+ interconversion between NH3 and N3-, which is reversible in the coordination spheres of Os complexes containing either tpm (tpm = tris(1-pyrazolyl)methane) or Tp (Tp = hydrotris(1-pyrazolyl)borate anion) ligands. Electrochemical or chemical reduction of the nitrido complexes [Os(VI)(tpm)(Cl)2(N)]+ (1) and Os(VI)(Tp)(Cl)2(N) (2) in acidic aqueous solution gives the corresponding Os(II)-ammine complexes, which, after air oxidation and workup, are isolated and structurally characterized as [Os(III)(tpm)(Cl)2(NH3)](PF6) (3) and Os(III)(Tp)(Cl)2(NH3) (4). The Os(III)-ammine complexes are reoxidized electrochemically to the nitrido complexes by stepwise mechanisms involving the loss of both electrons and protons and sequential Os(III-->IV) and Os(IV-->VI) oxidations.

Journal Article↗
PubMed2001

Atp11p and Atp12p are assembly factors for the F(1)-ATPase in human mitochondria.

Atp11p and Atp12p were first described as proteins required for assembly of the F(1) component of the mitochondrial ATP synthase in Saccharomyces cerevisiae (Ackerman, S. H., and Tzagoloff, A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4986-4990). Here we report the isolation of the cDNAs and the characterization of the human genes for Atp11p and Atp12p and show that the human proteins function like their yeast counterparts. Human ATP11 spans 24 kilobase pairs in 9 exons and maps to 1p32.3-p33, while ATP12 contains > or =8 exons and localizes to 17p11.2. Both genes are broadly conserved in eukaryotes and are expressed in a wide range of tissues, which suggests that Atp11p and Atp12p are essential housekeeping proteins of human cells. The information reported herein will be useful in the evaluation of patients with ascertained deficiencies in the ATP synthase, in which the underlying biochemical defect is unknown and may reside in a protein that influences the assembly of the enzyme.

Amino Acid Sequence↗
PubMed2001

Reactions of an amphoteric terminal tungsten methylidyne complex.

Treatment of [Tp'(CO)(2)W triple bond C--PPh(3)][PF(6)] (Tp' = hydridotris(3,5-dimethylpyrazolylborate)) with Na[HBEt(3)] in THF forms the methylidyne complex Tp'(CO)(2)W triple bond C--H via formyl and carbene intermediates Tp'(CO)(C(O)H)W triple bond C- PPh(3) and Tp'(CO)(2)W=C(PPh(3))(H), respectively. Spectroscopic features reported for Tp'(CO)(2)W triple bond C--H include the W triple bond C stretch (observed by both IR and Raman spectroscopy) and the (183)W NMR signal (detected by a (1)H, (183)W 2D HMQC experiment). Protonation of the Tp'(CO)(2)W triple bond C--H methylidyne complex with HBF(4).Et(2)O yields the cationic alpha-agostic methylidene complex [Tp'(CO)(2)W=CH(2)][BF(4)]. The methylidyne complex Tp'(CO)(2)W triple bond C-H can be deprotonated with alkyllithium reagents to provide the anionic terminal carbide Tp'(CO)(2)W triple bond C--Li; a downfield resonance at 556 ppm in the (13)C NMR spectrum has been assigned to the carbide carbon. The terminal carbide Tp'(CO)(2)W triple bond C-Li adds electrophiles at the carbide carbon to generate Tp'(CO)(2)W triple bond C--R (R = CH(3), SiMe(3), I, C(OH)Ph(2), CH(OH)Ph, and C(O)Ph) Fischer carbynes. A pK(a) of 28.7 was determined for Tp'(CO)(2)W triple bond C--H in THF by titrating the terminal carbide Tp'(CO)(2)W triple bond C--Li with 2-benzylpyridine and monitoring its conversion to Tp'(CO)(2)W triple bond C--H with in situ IR spectroscopy. Addition of excess Na[HBEt(3)] to neutral Tp'(CO)(2)W triple bond C--H generates the anionic methylidene complex [Na][Tp'(CO)(2)W=CH(2)]. The synthetic methodology for generating an anionic methylidene complex by hydride addition to neutral Tp'(CO)(2)W triple bond C--H contrasts with routes that utilize alpha-hydrogen abstraction or hydride removal from neutral methyl precursors to generate methylidene complexes. Addition of PhSSPh to the anionic methylidene complex in solution generates the saturated tungsten product Tp'(CO)(2)W(eta(2)-CH(2)SPh) by net addition of the SPh(+) moiety.

Journal Article↗
PubMed2001

Separation of positional isomers of oxidation catalyst precursors.

A series of polypyridyl ruthenium complexes of the general formula [Ru(tpy)(bpy')Cl]+ where tpy is 2,2':6',2"-terpyridine and bpy' is 4-carboxy-4'-methyl-2,2'-bipyridine (4-CO2H-4'-Mebpy), a proline derviative (4-CO-Pra-(Boc)(OMe)-4'-Mebpy), or 4-((diethoxyphosphinyl)methyl)-4'-methyl-2,2'-bipyridine (4-CH2PO3Et2-4'-Mebpy) are prepared. For each complex, two isomers exist, and these are separated chromatographically. The structure of the hexafluorophosphate salt of cis-[Ru(tpy)(4-CO2H-4'-Mebpy)Cl]+, cis-1, is determined by X-ray crystallography. The salt crystallizes in the monoclinic space group Cc with a = 12.4778(6) A, b = 12.6086(6) A, c = 20.1215(9) A, beta = 107.08200(1) degrees, Z = 4, R = 0.058, and Rw = 0.072. The structures of the remaining complexes are assigned by 1H NMR comparisons with cis-1. The complexes are potentially important precursors for the incorporation of RuIV=O2+ oxidants into polymers or peptides or for their adsorption onto oxide surfaces. Preliminary electrochemical results for the isomers of [Ru(tpy)(4-CH2PO3H2-4'-Mebpy)(H2O)]2+, 4, adsorbed on ITO (In2O3:Sn) surfaces add support to a recently proposed electron-transfer mechanism involving cross-surface proton-coupled electron transfer.

Journal Article↗
PubMed2001

Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.

Loss of heterozygosity of several specific genomic regions is frequently observed in neuroblastoma tumors and cell lines, but homozygous deletion (HD) is rare, and no neuroblastoma tumor suppressor gene (TSG) has yet been identified. We performed a systematic search for HD, indicative of a disrupted TSG, in a panel of 46 neuroblastoma cell lines. An initial search focused on a well-characterized consensus region of hemizygous deletion at 1p36.3, which occurs in 35% of primary neuroblastomas. Each cell line was screened with 162 1p36 markers, for a resolution of 13 kb within the consensus 1p36.3 deletion region and 350 kb throughout the remainder of 1p36. No HDs were detected. This approach was expanded to survey 21 known TSGs, specifically targeting intragenic regions frequently inactivated in other malignancies. HD was detected only at the CDKN2A (p16INK4a/p14ARF) gene at 9p21 and was observed in 4 of 46 cell lines. The observed region of HD included all exons of both CDKN2A and the closely linked CDKN2B (p15INK4b) gene for cell lines LA-N-6 and CHLA-174, all exons of CDKN2A but none of CDKN2B for CHLA-179, and only 104 bp within CDKN2A exon 2 for CHLA-101. All four deletions are predicted to inactivate the coding regions of both p16INK4a and p14ARF. HD was observed in corresponding primary tumor samples for CHLA-101 and CHLA-174 but was not present in constitutional samples. These results suggest that for neuroblastoma, large HDs do not occur within 1p36, most known TSGs are not homozygously deleted, and biallelic inactivation of CDKN2A may contribute to tumorigenicity in a subset of cases.

Blotting, Southern↗
PubMed2001

Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma.

BACKGROUND: Neuroblastoma tumorigenesis may involve the differential inactivation of multiple tumor suppressor genes. Recent data have suggested that a neuroblastoma suppressor gene may be located on the long arm of chromosome 11 (11q). PROCEDURE: We therefore analyzed 295 primary neuroblastomas from a representative group of patients for loss of heterozygosity (LOH) at 25 polymorphic markers spanning 11q. RESULTS: LOH was observed in 129 primary neuroblastomas (44%), and a common region of LOH mapped to 11q14-23. No correlation was found between 11q LOH and adverse prognostic variables, but a strong inverse relationship between 11q LOH and MYCN amplification (P < 0.001) was observed. There was no difference in overall survival when patients were stratified by 11q LOH status. However, 11q LOH was associated with a decreased overall survival probability when patients whose tumors had a single copy of MYCN were analyzed separately (P = 0.008). CONCLUSION: These data support the hypothesis that a tumor suppressor gene mapping within 11q14-23 is frequently inactivated during the malignant evolution of neuroblastoma.

Alleles↗
PubMed2001

Loss of heterozygosity for chromosome 14q in neuroblastoma.

BACKGROUND: Neuroblastoma is a genetically heterogeneous disease, with subsets of tumors demonstrating rearrangements of several genomic regions. Preliminary studies from several groups have identified loss of heterozygosity (LOH) for the long arm of chromosome 14 (14q) in 20-25% of primary neuroblastomas. PROCEDURE: To determine precisely the frequency and extent of 14q deletions, we performed LOH analysis for a large series of primary neuroblastomas using a panel of 11 highly polymorphic markers. RESULTS: LOH was detected in 83 of 372 tumors (22%). Although the majority of tumors with allelic loss demonstrated allelic loss for all informative markers, 13 cases showed LOH for only a portion of 14q. A single consensus region of deletion, which was shared by all tumors with 14q LOH, was defined within 14q23-q32 between D14S588 and the 14q telomere. Allelic loss for 14q was strongly correlated with the presence of 11q LOH (P < 0.001 ) and inversely correlated with MYCN amplification (P= 0.04). CONCLUSIONS: LOH for 14q was evident in all clinical risk groups, indicating that this abnormality may be a universal feature of neuroblastoma tumor development. These findings suggest that a tumor suppressor gene involved in the initiation or progression of neuroblastoma is located within distal 14q.

Child↗
PubMed2001

Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

BACKGROUND: Chromosome 1p deletions are common in advanced neuroblastomas, but the biological and clinical implications of this clonal rearrangement remain controversial. Previous studies of chromosome 1p loss of heterozygosity (LOH) have been limited by analyses of relatively small number of tumors derived from heterogeneously assessed and treated patient populations. Therefore, a strictly representative cohort of 288 Children's Cancer Group neuroblastoma patients treated on the most recent phase III therapeutic trials was identified. PROCEDURE: Primary tumors from these patients were analyzed for LOH at precisely mapped and highly informative 1p polymorphic loci located from 1p32 to 1p36.3 by multiplex PCR. RESULTS: Ninety-three primary tumor specimens (32%) had LOH at multiple 1p36 marker loci. All 1p deletions overlapped the previously determined smallest region of overlap (SRO). One tumor had a small terminal deletion completely within 1p36.3, allowing for further refinement of the 1p36 SRO. We found no evidence to support an additional, nonoverlapping region of LOH within 1p32-36. We confirmed the strong correlation of 1p36 LOH with MYCN amplification (P < 0.001), advanced disease stage (P < 0.001), and decreased both 3-year event-free survival and overall survival probabilities (P< 0.001). When stratified for MYCN amplification status or entered into a multivariate analysis, 1p36 LOH remained predictive for decreased event-free survival, but not overall survival probability. CONCLUSIONS: These data support the hypothesis that inactivation of a tumor suppressor gene within 1p36.3 is associated with an increased risk for disease relapse.

Alleles↗